- Home
- SKE vs WGS Comparison
SKE vs WGS Comparison
Compare SKE & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKE
- WGS
- Stock Information
- Founded
- SKE 1979
- WGS 2017
- Country
- SKE Canada
- WGS United States
- Employees
- SKE N/A
- WGS N/A
- Industry
- SKE Precious Metals
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- SKE Basic Materials
- WGS Technology
- Exchange
- SKE Nasdaq
- WGS Nasdaq
- Market Cap
- SKE 2.1B
- WGS 2.4B
- IPO Year
- SKE N/A
- WGS N/A
- Fundamental
- Price
- SKE $17.69
- WGS $126.46
- Analyst Decision
- SKE
- WGS Strong Buy
- Analyst Count
- SKE 0
- WGS 8
- Target Price
- SKE N/A
- WGS $130.63
- AVG Volume (30 Days)
- SKE 600.5K
- WGS 626.6K
- Earning Date
- SKE 11-13-2025
- WGS 10-28-2025
- Dividend Yield
- SKE N/A
- WGS N/A
- EPS Growth
- SKE N/A
- WGS N/A
- EPS
- SKE N/A
- WGS 0.07
- Revenue
- SKE N/A
- WGS $402,190,000.00
- Revenue This Year
- SKE N/A
- WGS $39.54
- Revenue Next Year
- SKE N/A
- WGS $22.50
- P/E Ratio
- SKE N/A
- WGS $1,777.01
- Revenue Growth
- SKE N/A
- WGS 50.50
- 52 Week Low
- SKE $7.32
- WGS $55.17
- 52 Week High
- SKE $20.77
- WGS $147.71
- Technical
- Relative Strength Index (RSI)
- SKE 53.85
- WGS 44.31
- Support Level
- SKE $16.75
- WGS $119.43
- Resistance Level
- SKE $18.44
- WGS $147.71
- Average True Range (ATR)
- SKE 0.65
- WGS 9.03
- MACD
- SKE 0.20
- WGS -1.56
- Stochastic Oscillator
- SKE 74.66
- WGS 24.08
About SKE Skeena Resources Limited
Skeena Resources Ltd is a mining company in development stage focusing on the construction and development of the Eskay Creek project in British Columbia. Eskay Creek is the next global gold development project and represents one of the highest-grade and lowest-cost open-pit precious metals mines, with substantial silver by-product production.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.